Ordering
Available Variants10 mg
CHA.58232-10mg
Price
€150.40
Available – Dispatch in 14 days
50 mg
CHA.58232-50mg
Price
€454.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.58232-10mg | €150.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.58232-50mg | €454.40 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C12H10FN3O4 |
|---|---|
| CAS Number | 136087-85-9 |
| Molecular Weight | 279.22 |
| MDL number | MFCD00919183 |
| NACRES | NA.28 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Fidarestat, also known by its CAS number 136087-85-9, is a potent aldose reductase inhibitor that has been investigated for its potential therapeutic applications. Aldose reductase is an enzyme involved in the polyol pathway, which plays a significant role in the development of complications associated with diabetes mellitus. By inhibiting this enzyme, fidarestat aims to prevent the conversion of glucose to sorbitol, thereby reducing the accumulation of sorbitol in tissues and mitigating the resulting oxidative stress and damage. Fidarestat has been studied in various preclinical and clinical trials, demonstrating its efficacy in reducing the severity of diabetic neuropathy and other complications. Its mechanism of action and potential benefits make fidarestat a promising candidate for the treatment of diabetes-related disorders, although further research is necessary to fully elucidate its therapeutic potential and safety profile.
